Helix BioPharma Corp. Announces Appointment of Interim Chief Executive Officer

RICHMOND HILL, ONTARIO – Helix BioPharma Corp. (TSX: HBP) (“Helix” or the “Company”), an immuno-oncology
company developing innovative drug candidates for the prevention and treatment of cancer, today announced that
the Company’s Chairman of the Board, Prof. Dr. Slawomir Majewski, will immediately assume the role of Interim CEO
while the Company continues to identify and evaluate candidates.

2021-09-21 HBP PR – Announces Appointment